Clinical Trial

Association Between Early FiO₂ Exposure and Changes in the Uric Acid/Albumin Ratio in Septic ICU Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective, non-interventional study aims to investigate the relationship between early oxygen exposure and oxidative stress in adult intensive care unit (ICU) patients diagnosed with sepsis or septic shock. Fraction of inspired oxygen (FiO₂) levels administered during the first 24 hours of ICU admission will be evaluated in relation to changes in the uric acid/albumin ratio (UAR), a biochemical marker reflecting oxidative burden and inflammation. Serum uric acid and albumin levels will be measured at ICU admission and at 24 hours, and the percentage change in UAR (ΔUAR%) will be calculated. Associations between FiO₂ exposure parameters and ΔUAR% will be analyzed, along with secondary outcomes including 28-day mortality and oxygenation indices. The findings may help clarify whether excessive oxygen therapy contributes to oxidative stress and whether UAR can serve as an accessible biomarker of oxygen-related oxidative injury in septic ICU patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-31.
Trial Details
NCT Number NCT07332637
Lead Sponsor Istinye University
Conditions Hyperoxia / High FiO₂ Exposure, Uric Acid/Albumin Ratio (UAR)
Enrollment 110 participants
Start Date 2026-01-15
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-13